Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yongxiu Yang has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaolei Liang

    Department of Obstetrics and Gynecology, Gansu Provincial Clinical Research Center for Gynecological Oncology, Branch of National Clinical Research Center for Gynecology and Obstetrics, The First Hospital of Lanzhou University , Lanzhou, 730030

    12 shared publications
  • Dan Hu

    Department of Obstetrics and Gynecology, The First Hospital of Lanzhou University, Lanzhou, China

    10 shared publications
  • Junhong Du

    Department of Obstetrics and Gynecology, The First Hospital of Lanzhou University, Lanzhou, China

    10 shared publications
  • Xi Chen

    The First School of Clinical Medicine Lanzhou University Lanzhou China

    9 shared publications
  • Yijuan Xing

    Department of Obstetrics and Gynecology, The First Hospital of Lanzhou University, Lanzhou, China

    9 shared publications
  • Xiaolei Liang

    Department of Obstetrics and Gynecology, the First Hospital of Lanzhou University, Gansu Provincial Clinical Research Center for Gynecological Oncology, Branch of National Clinical Research Center for Gynecology and Obstetrics, Lanzhou, Gansu 730000, China

    8 shared publications

Latest Publications

  • Analysis of the Correlation between the Pan-immune Inflammation Value and the Prognosis of Patients with Endometrial Cancer

    by Wenhua Wang, Yanbin Jin, Yongxiu Yang

    Immune and inflammatory factors influence endometrial cancer outcomes, the pan-immune inflammation value (PIV) shows potential but remains underexplored. This study aims to evaluate the relationship between preoperative PIV, T cell subtypes, and surgical prognosis in endometrial cancer patients, providing insights for prognostic markers and predictive models. We conducted a prospective observational study involving 101 endometrial cancer patients from August 2022 to August 2024. Based on prognosis within 6 months post-surgery, patients were divided into good and poor prognosis groups. We compared clinical characteristics, inflammatory indices, and T cell immune profiles between the groups. The mean age of participants was 50.12 years, with 23 patients experiencing a poor prognosis. The poor prognosis group exhibited significantly higher proportions of advanced International Federation of Gynecology and Obstetrics (FIGO) stage, larger tumor diameter, elevated neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and PIV. Conversely, this group showed lower proportions receiving neoadjuvant chemotherapy, CD4+ T cells, and CD4+CD8+ T cell ratios. Notably, elevated PIV emerged as an independent risk factor for poor prognosis, while increased CD4+ T cell proportion and CD4+CD8+ ratio were protective. PIV is significantly associated with poor prognosis in endometrial cancer, serving as an independent risk factor. Higher CD4+ T cell counts and CD4+:CD8+ ratios provide protective benefits. The constructed logistic regression model demonstrates strong predictive capability for post-surgical outcomes. However, limitations, including sample size and short follow-up, necessitate further investigation in larger cohorts.

  • Open Access

    CKAP2L promotes endometrial cancer progression by suppressing AKT ubiquitination and activating the PI3K/AKT signaling pathway

    by Min Wei, Xuefei Bai, Lili Xi, Yongxiu Yang

    Objective: Cytoskeleton-associated protein 2-like (CKAP2L), a microtubule-associated protein that serves as a structural component of the spindle pole and a cell cycle-related protein, acts as an oncogene in several cancers. This study seeks to elucidate the role of CKAP2L in endometrial cancer (EC) and to investigate its underlying mechanisms. Methods: The correlation between CKAP2L and clinical features was analyzed utilizing bioinformatics approaches. The expression of CKAP2L, Ki-67, and PCNA was evaluated using immunohistochemistry. Xenograft mouse models were established for in vivo validation. Colony formation, EdU, CCK8, flow cytometry analysis, transwell, and scratch assays were performed to assess the impact of CKAP2L on EC cell malignant properties. The Phalloidin staining assay was used to evaluate actin cytoskeletal remodeling. The level of CKAP2L, Cleaved-Caspase-3, Bax, Bcl-2, CDK1, Cyclin B1, p27, p21, and PI3K/AKT was analyzed by Western blotting analysis. Co-immunoprecipitation (Co-IP) and ubiquitination assays were conducted to investigate the interaction between CKAP2L and AKT. Results: CKAP2L was elevated in EC tissues. In vivo experiments revealed that CKAP2L knockdown attenuated EC growth. In vitro experiments showed CKAP2L depletion inhibited EC cell proliferation, migration, invasion, and F-actin formation, while triggering apoptosis and cell cycle arrest. Conversely, CKAP2L overexpression produced the opposite effects. Cycloheximide chase and MG132 assays revealed CKAP2L stabilized p-AKT by inhibiting ubiquitin-proteasome degradation. Overexpressing CKAP2L decreased AKT ubiquitination and activated PI3K/AKT signaling. Conclusions: CKAP2L enhances the malignant behavior and actin cytoskeleton remodeling of EC cells by decreasing AKT ubiquitination, sustaining AKT phosphorylation, and activating the PI3K/AKT signaling pathway. This indicates that CKAP2L could be a promising therapeutic target for EC.

  • Pharmacological Treatment for Gestational Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis of 71 Randomised Controlled Trial

    by Xiaowei Liu, Bei Pan, Danni Xia, Xin He, Weize Kong, Junliang Tao, Ning Ma, Xi Chen, Peichen Xiao, Junfen Li, et al.

    Aims: Pharmacologic treatment is widely used for managing gestational diabetes mellitus (GDM). However, evidence remains limited on the comparative effectiveness and safety across different drug classes for GDM. This study aims to compare the efficacy and safety of pharmacologic treatments for GDM using network meta‐analysis of randomised controlled trials (RCTs). Materials and Methods: We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science up to May 16, 2025 to identify trials evaluating glucose levels and maternal or neonatal complications in GDM patients using any pharmacologic agents, e.g., insulin, biguanides, sulfonylureas, α‐glycosidase inhibitors, sodium‐glucose cotransporter‐2(SGLT‐2) inhibitors, dipeptidyl peptidase IV(DPP‐IV) inhibitors or Glucagon‐like peptide‐1receptor (GLP‐1 RAs) versus standard care. We used random‐effects model for both pairwise meta‐analyses and frequentist network meta‐analyses and applied the Confidence in Network Meta‐Analysis (CINeMA) framework to assess the certainty of evidence. Results: Seventy‐three articles were eligible, comprising 71 trials in which 14 877 participants were enrolled and seven drug classes assessed. All subsequent effects refer to comparisons with standard care. Because of their moderate to high evidence of certainty, sulfonylureas were established as the most effective drugs used for lowering fasting glucose (mean difference [MD]: −0.33 mmol/L; 95% confidence interval [CI]: −0.55 to −0.1), followed by insulin (MD: −0.3 mmol/L; 95% CI: −0.4 to −0.21) and biguanides (MD: −0.2 mmol/L; 95% CI: −0.28 to −0.12). Biguanides were the most effective drugs used to control haemoglobin A1c (MD: −0.1%; 95% CI: −0.16 to −0.03), but their use was associated with increased adverse events leading to low birth weight among infants (OR: 2.04; 95% CI: 1.04–4.01). Insulin (OR: 0.51; 95% CI: 0.34–0.75), biguanides (OR: 0.39; 95% CI: 0.26–0.59), and sulfonylureas (OR: 0.5; 95% CI: 0.31–0.79) use could decrease the risk of macrosomia. Sulfonylureas were found to be more easily get premature delivery and neonatal hypoglycaemia than biguanides; evidence regarding their impact on low birth weight and long‐term safety remains lacking. Conclusion: Insulin use provides significant benefits in achieving glycaemic control and minimising maternal and foetal complications, and it has a favourable overall safety profile. Biguanide use may be associated with an increased risk of low birth weight, warranting careful consideration and thorough counselling for shared decision‐making. Currently, insufficient evidence supporting the efficacy and safety of sulfonylureas, α‐glycosidase, DPP‐IV, and SGLT‐2 inhibitors; and GLP‐1 RAs in GDM management is available.


  • Open Access

    MTFR2 regulated the proliferation, apoptosis, migration, and invasion of endometrial cancer cells through the Drp1/MFN1 signaling pathway mediated mitochondrial fission

    by Xuefei Bai, Min Wei, Qi Wang, Yongxiu Yang

    Background: Mitochondrial dynamics play a critical role in tumor progression, yet the contribution of mitochondrial fission regulator 2 (MTFR2) to endometrial cancer (EC) remains poorly defined. This study investigated the clinical relevance and functional role of MTFR2 in EC and explored its involvement in mitochondrial dynamics mediated by the dynamin-related protein 1 (Drp1)/mitochondrial fusion protein mitofusin 1 (MFN1) signaling axis. Methods: The expression levels of MTFR2 in EC tissues and normal endometrial tissues were analyzed using quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry (IHC). The effects of MTFR2 on the proliferation, apoptosis, migration, and invasion abilities of EC cells were evaluated using Cell Counting Kit-8 (CCK-8), colony formation, 5-ethynyl-2'-deoxyuridine (EdU), scratch wound healing, and Transwell assays. A nude mouse subcutaneous xenograft tumor model was constructed to verify the role of MTFR2 in vivo, and changes in the activity of the Drp1/MFN1 signaling pathway were detected. Results: MTFR2 was significantly upregulated in EC tissues associated with patient age, clinical stage, pathological type, histological grade, depth of tumor invasion, and treatment response. Overexpression of MTFR2 promoted the proliferation, clonogenicity, DNA synthesis, migration, and invasion of EC cells; in contrast, knockdown of MTFR2 inhibited these malignant phenotypes. Additionally, MTFR2 regulated the activity of the Drp1/MFN1 signaling pathway: its overexpression increased Drp1 phosphorylation and decreased MFN1 expression, whereas MTFR2 knockdown reduced Drp1 phosphorylation and increased MFN1 levels. In vivo experiments demonstrated that silencing MTFR2 significantly suppressed subcutaneous tumor growth in nude mice and reduced the expression of Ki-67 and proliferating cell nuclear antigen (PCNA) in tumor tissues. Conclusions: MTFR2 is highly expressed in EC and is correlated with a poor prognosis and aggressive tumor behavior. It promotes proliferation, apoptosis, migration, and invasion of EC cells by regulating the Drp1/MFN1 signaling pathway. This suggests that MTFR2 could potentially be a molecular target for the diagnosis and treatment of EC.

  • Open Access

    Integrative network toxicology and experimental evidence reveal mechanisms underlying diethyl phthalate-induced initiation and progression of endometrial cancer

    by Xi Chen, Zijing Wang, Fengfeng Wang, Yuexiao Wu, Dan Hu, Yuemei Cheng, Yijuan Xing, Junhong Du, Tao Jiang, Yongxiu Yang, et al.

    Diethyl phthalate (DEP) is a ubiquitous environmental endocrine-disrupting chemical (EDC). Epidemiological studies have suggested a potential association between DEP exposure and an increased risk of endometrial cancer (EC); however, its underlying molecular mechanisms remain largely unclear. Four GEO datasets were integrated, and differential expression analysis combined with weighted gene co-expression network analysis (WGCNA) was performed to identify candidate genes potentially linking DEP exposure to EC. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted to explore relevant signaling pathways. Machine learning models, coupled with Shapley Additive Explanations (SHAP), were employed to prioritize key genes. Molecular docking and molecular dynamics (MD) simulations were used to assess the binding affinity between DEP and the identified targets. A series of in vitro experiments in EC cell lines were subsequently conducted to validate the biological effects of DEP. Nineteen overlapping DEP–EC genes were identified, predominantly enriched in the MAPK, cAMP, and cGMP–PKG signaling pathways. Among them, FOS, NR4A1, ADRA2C, JUN, and SLC6A2 were prioritized as core genes through machine learning and SHAP analysis. Molecular simulations confirmed stable binding between DEP and these targets. In vitro assays demonstrated that DEP exposure induces oxidative stress, significantly enhances ERK1/2 and AKT phosphorylation, upregulates Cyclin D1/CDK4 expression, promotes G1/S phase transition, and facilitates EC cell proliferation. These findings suggest that DEP may promote endometrial carcinogenesis by triggering oxidative stress-mediated signaling crosstalk and accelerating cell cycle progression. This study establishes a multi-layered methodological framework-from computational screening and machine learning to experimental validation-offering novel mechanistic insights into the carcinogenic potential of environmental endocrine disruptors such as DEP.


  • Open Access

    Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma

    by Xi Chen, Ruiyue Wu, Zijing Wang, Fengfeng Wang, Dan Hu, Xuehan Bi, Xiaolei Liang, Yongxiu Yang

    Objective: The calcium-dependent activator protein for secretion (CAPS) has emerged as a protein of interest in tumor biology; however, its functional significance in endometrial carcinoma (EC) remains largely unexplored. Methods: We performed an integrative analysis leveraging bulk RNA sequencing data from The Cancer Genome Atlas, GTEx, and publicly available EC datasets, coupled with gene set enrichment analysis (GSEA) and single-cell transcriptomic profiling. The association between CAPS expression and clinicopathological parameters as well as patient prognosis was systematically assessed. In addition, functional enrichment, intercellular communication, and immune infiltration analyses were conducted to elucidate the molecular and microenvironmental roles of CAPS. In vitro assays were employed to validate the biological effects of CAPS knockdown on EC cell proliferation, migration, and invasion. Results: CAPS was significantly upregulated in early-stage, low-grade, and endometrioid endometrial carcinoma, and its elevated expression was associated with improved patient survival. GSEA indicated that high CAPS expression was correlated with enhanced ribosome biogenesis and oxidative phosphorylation, along with suppression of proliferative signaling, reflecting a metabolically differentiated phenotype. Single-cell transcriptomic analysis revealed that CAPS was specifically enriched in terminally differentiated secretory epithelial cells, promoting epithelial maturation and oxidative metabolism. Furthermore, CAPS-positive cells exhibited extensive crosstalk with immune cells, suggesting a potential role in facilitating anti-tumor immune responses. Functional assays confirmed that CAPS knockdown markedly enhanced EC cell proliferation, migration, and invasion. Conclusion: CAPS may act as a tumor suppressor in EC by stabilizing microtubule architecture, reprogramming cellular metabolism, and modulating immune interactions within the tumor microenvironment. These findings highlight CAPS as a promising prognostic biomarker and potential therapeutic target in EC.


  • ACSL4 coordinates metabolic and cell cycle reprogramming to promote endometrial cancer progression

    by Hongtao Guo, Yitong Ma, Liangjian Ma, Xiaolei Liang, Hongli Li, Chang Liu, Yongxiu Yang